This page was reviewed but not written by the grant investigators. Kainomyx staff also reviewed this page prior to publication.
Open Philanthropy recommended an investment of $1,999,999 in Kainomyx to develop and produce a new antimalarial drug. If effective, the new drug would act by inhibiting cytoskeletal proteins in malarial parasites. Our science team believes that there is a need for new antimalarial drugs due to increasing artemisinin resistance to existing treatments.